AG真人官方

STOCK TITAN
  1. Home
  2. Sec-filings
  3. RXRX
  4. [Form 4] Recursion Pharmaceuticals, Inc. Insider Trading Activity

[Form 4] Recursion Pharmaceuticals, Inc. Insider Trading Activity

Filing Impact
(Neutral)
Filing Sentiment
(Neutral)
Form Type
4
Rhea-AI Filing Summary

Recursion Pharmaceuticals (RXRX) Director Zavain Dar received new equity compensation grants on June 18, 2025, consisting of:

  • 22,016 restricted stock units (RSUs) that will vest on the earlier of June 18, 2026, or the day before the 2026 Annual Meeting
  • 44,031 stock options with an exercise price of $5.11, exercisable until June 18, 2035, vesting on the same schedule as the RSUs

Following these transactions, Dar directly owns 132,893 shares of Class A Common Stock and 44,031 stock options. Both grants are subject to continued service as a director. These awards were automatically granted according to the company's Outside Director Compensation Policy, representing standard board compensation arrangements.

Zavain Dar, Direttore di Recursion Pharmaceuticals (RXRX), ha ricevuto nuove assegnazioni di compensi azionari il 18 giugno 2025, composte da:

  • 22.016 unit脿 di azioni vincolate (RSU) che matureranno al pi霉 tardi il 18 giugno 2026 o il giorno prima dell'Assemblea Annuale del 2026
  • 44.031 opzioni su azioni con un prezzo di esercizio di 5,11 dollari, esercitabili fino al 18 giugno 2035, con maturazione secondo lo stesso calendario delle RSU

Dopo queste operazioni, Dar possiede direttamente 132.893 azioni di Classe A e 44.031 opzioni su azioni. Entrambe le assegnazioni sono vincolate alla continuazione del suo ruolo di direttore. Questi premi sono stati concessi automaticamente in base alla Politica di Compenso per Direttori Esterni della societ脿, rappresentando le consuete modalit脿 di remunerazione del consiglio.

Zavain Dar, Director de Recursion Pharmaceuticals (RXRX), recibi贸 nuevas concesiones de compensaci贸n en acciones el 18 de junio de 2025, que consisten en:

  • 22,016 unidades de acciones restringidas (RSU) que se consolidar谩n a m谩s tardar el 18 de junio de 2026 o el d铆a antes de la Junta Anual de 2026
  • 44,031 opciones sobre acciones con un precio de ejercicio de $5.11, ejercitables hasta el 18 de junio de 2035, con consolidaci贸n en el mismo calendario que las RSU

Tras estas transacciones, Dar posee directamente 132,893 acciones ordinarias Clase A y 44,031 opciones sobre acciones. Ambas concesiones est谩n sujetas a la continuidad en su cargo como director. Estos premios se otorgaron autom谩ticamente conforme a la Pol铆tica de Compensaci贸n para Directores Externos de la empresa, representando los arreglos est谩ndar de remuneraci贸n del consejo.

Recursion Pharmaceuticals(RXRX) 鞚挫偓 鞛愲矤鞚� 雼るゴ電� 2025雲� 6鞗� 18鞚检棎 雼れ潓瓿� 臧欖潃 靸堧鞖� 欤检嫕 氤挫儊 攵�鞐ゼ 氚涭晿鞀惦媹雼�:

  • 22,016臧滌潣 鞝滍暅 欤检嫕 雼渼(RSU)電� 2026雲� 6鞗� 18鞚� 霕愲姅 2026雲� 鞐半 齑濏殞 鞝勲偁 欷� 牍犽ジ 鞁滌澕鞐� 甓岆Μ臧� 頇曥爼霅╇媹雼�
  • 44,031臧滌潣 欤检嫕 毵れ垬 鞓奠厴鞙茧 頄夓偓 臧�瓴╈潃 $5.11鞚措┌, 2035雲� 6鞗� 18鞚缄箤歆� 頄夓偓 臧�電ロ晿瓿� RSU鞕� 霃欖澕頃� 鞚检爼鞙茧 甓岆Μ臧� 頇曥爼霅╇媹雼�

鞚� 瓯半灅霌� 鞚错泟 雼るゴ電� 歆侅爲鞝侅溂搿� 韥措灅鞀� A 氤错喌欤� 132,893欤检檧 欤检嫕 毵れ垬 鞓奠厴 44,031欤茧ゼ 氤挫湢頃橁矊 霅╇媹雼�. 霊� 攵�鞐� 氇憪 鞚挫偓歆侅潉 瓿勳啀 靾橅枆頃橂姅 臁瓣贝鞚� 攵欖柎 鞛堨姷雼堧嫟. 鞚� 氤挫儊鞚� 須岇偓鞚� 鞕鸽秬 鞚挫偓 氤挫儊 鞝曥眳鞐� 霐半澕 鞛愲彊鞙茧 攵�鞐悳 瓴冹溂搿�, 響滌 鞚挫偓須� 氤挫儊 觳搓硠毳� 氚橃榿頃╇媹雼�.

Zavain Dar, administrateur de Recursion Pharmaceuticals (RXRX), a re莽u de nouvelles attributions de r茅mun茅ration en actions le 18 juin 2025, comprenant :

  • 22 016 unit茅s d鈥檃ctions restreintes (RSU) qui seront acquises au plus tard le 18 juin 2026 ou la veille de l鈥檃ssembl茅e g茅n茅rale annuelle 2026
  • 44 031 options d鈥檃chat d鈥檃ctions avec un prix d鈥檈xercice de 5,11 $, exer莽ables jusqu鈥檃u 18 juin 2035, avec une acquisition selon le m锚me calendrier que les RSU

Apr猫s ces op茅rations, Dar d茅tient directement 132 893 actions ordinaires de classe A et 44 031 options d鈥檃chat d鈥檃ctions. Ces deux attributions sont conditionn茅es 脿 la poursuite de son mandat d鈥檃dministrateur. Ces r茅compenses ont 茅t茅 attribu茅es automatiquement conform茅ment 脿 la politique de r茅mun茅ration des administrateurs externes de la soci茅t茅, repr茅sentant les arrangements standards de r茅mun茅ration du conseil.

Zavain Dar, Direktor von Recursion Pharmaceuticals (RXRX), erhielt am 18. Juni 2025 neue Aktienverg眉tungen, bestehend aus:

  • 22.016 Restricted Stock Units (RSUs), die sp盲testens am 18. Juni 2026 oder am Tag vor der Hauptversammlung 2026 unverfallbar werden
  • 44.031 Aktienoptionen mit einem Aus眉bungspreis von 5,11 USD, aus眉bbar bis zum 18. Juni 2035, mit derselben Vesting-Regelung wie die RSUs

Nach diesen Transaktionen besitzt Dar direkt 132.893 Aktien der Klasse A Stammaktien sowie 44.031 Aktienoptionen. Beide Zuteilungen unterliegen der Bedingung der fortgesetzten T盲tigkeit als Direktor. Diese Zuwendungen wurden automatisch gem盲脽 der Verg眉tungspolitik f眉r externe Direktoren des Unternehmens gew盲hrt und stellen die 眉blichen Vorstandsverg眉tungsregelungen dar.

Positive
  • None.
Negative
  • None.

Zavain Dar, Direttore di Recursion Pharmaceuticals (RXRX), ha ricevuto nuove assegnazioni di compensi azionari il 18 giugno 2025, composte da:

  • 22.016 unit脿 di azioni vincolate (RSU) che matureranno al pi霉 tardi il 18 giugno 2026 o il giorno prima dell'Assemblea Annuale del 2026
  • 44.031 opzioni su azioni con un prezzo di esercizio di 5,11 dollari, esercitabili fino al 18 giugno 2035, con maturazione secondo lo stesso calendario delle RSU

Dopo queste operazioni, Dar possiede direttamente 132.893 azioni di Classe A e 44.031 opzioni su azioni. Entrambe le assegnazioni sono vincolate alla continuazione del suo ruolo di direttore. Questi premi sono stati concessi automaticamente in base alla Politica di Compenso per Direttori Esterni della societ脿, rappresentando le consuete modalit脿 di remunerazione del consiglio.

Zavain Dar, Director de Recursion Pharmaceuticals (RXRX), recibi贸 nuevas concesiones de compensaci贸n en acciones el 18 de junio de 2025, que consisten en:

  • 22,016 unidades de acciones restringidas (RSU) que se consolidar谩n a m谩s tardar el 18 de junio de 2026 o el d铆a antes de la Junta Anual de 2026
  • 44,031 opciones sobre acciones con un precio de ejercicio de $5.11, ejercitables hasta el 18 de junio de 2035, con consolidaci贸n en el mismo calendario que las RSU

Tras estas transacciones, Dar posee directamente 132,893 acciones ordinarias Clase A y 44,031 opciones sobre acciones. Ambas concesiones est谩n sujetas a la continuidad en su cargo como director. Estos premios se otorgaron autom谩ticamente conforme a la Pol铆tica de Compensaci贸n para Directores Externos de la empresa, representando los arreglos est谩ndar de remuneraci贸n del consejo.

Recursion Pharmaceuticals(RXRX) 鞚挫偓 鞛愲矤鞚� 雼るゴ電� 2025雲� 6鞗� 18鞚检棎 雼れ潓瓿� 臧欖潃 靸堧鞖� 欤检嫕 氤挫儊 攵�鞐ゼ 氚涭晿鞀惦媹雼�:

  • 22,016臧滌潣 鞝滍暅 欤检嫕 雼渼(RSU)電� 2026雲� 6鞗� 18鞚� 霕愲姅 2026雲� 鞐半 齑濏殞 鞝勲偁 欷� 牍犽ジ 鞁滌澕鞐� 甓岆Μ臧� 頇曥爼霅╇媹雼�
  • 44,031臧滌潣 欤检嫕 毵れ垬 鞓奠厴鞙茧 頄夓偓 臧�瓴╈潃 $5.11鞚措┌, 2035雲� 6鞗� 18鞚缄箤歆� 頄夓偓 臧�電ロ晿瓿� RSU鞕� 霃欖澕頃� 鞚检爼鞙茧 甓岆Μ臧� 頇曥爼霅╇媹雼�

鞚� 瓯半灅霌� 鞚错泟 雼るゴ電� 歆侅爲鞝侅溂搿� 韥措灅鞀� A 氤错喌欤� 132,893欤检檧 欤检嫕 毵れ垬 鞓奠厴 44,031欤茧ゼ 氤挫湢頃橁矊 霅╇媹雼�. 霊� 攵�鞐� 氇憪 鞚挫偓歆侅潉 瓿勳啀 靾橅枆頃橂姅 臁瓣贝鞚� 攵欖柎 鞛堨姷雼堧嫟. 鞚� 氤挫儊鞚� 須岇偓鞚� 鞕鸽秬 鞚挫偓 氤挫儊 鞝曥眳鞐� 霐半澕 鞛愲彊鞙茧 攵�鞐悳 瓴冹溂搿�, 響滌 鞚挫偓須� 氤挫儊 觳搓硠毳� 氚橃榿頃╇媹雼�.

Zavain Dar, administrateur de Recursion Pharmaceuticals (RXRX), a re莽u de nouvelles attributions de r茅mun茅ration en actions le 18 juin 2025, comprenant :

  • 22 016 unit茅s d鈥檃ctions restreintes (RSU) qui seront acquises au plus tard le 18 juin 2026 ou la veille de l鈥檃ssembl茅e g茅n茅rale annuelle 2026
  • 44 031 options d鈥檃chat d鈥檃ctions avec un prix d鈥檈xercice de 5,11 $, exer莽ables jusqu鈥檃u 18 juin 2035, avec une acquisition selon le m锚me calendrier que les RSU

Apr猫s ces op茅rations, Dar d茅tient directement 132 893 actions ordinaires de classe A et 44 031 options d鈥檃chat d鈥檃ctions. Ces deux attributions sont conditionn茅es 脿 la poursuite de son mandat d鈥檃dministrateur. Ces r茅compenses ont 茅t茅 attribu茅es automatiquement conform茅ment 脿 la politique de r茅mun茅ration des administrateurs externes de la soci茅t茅, repr茅sentant les arrangements standards de r茅mun茅ration du conseil.

Zavain Dar, Direktor von Recursion Pharmaceuticals (RXRX), erhielt am 18. Juni 2025 neue Aktienverg眉tungen, bestehend aus:

  • 22.016 Restricted Stock Units (RSUs), die sp盲testens am 18. Juni 2026 oder am Tag vor der Hauptversammlung 2026 unverfallbar werden
  • 44.031 Aktienoptionen mit einem Aus眉bungspreis von 5,11 USD, aus眉bbar bis zum 18. Juni 2035, mit derselben Vesting-Regelung wie die RSUs

Nach diesen Transaktionen besitzt Dar direkt 132.893 Aktien der Klasse A Stammaktien sowie 44.031 Aktienoptionen. Beide Zuteilungen unterliegen der Bedingung der fortgesetzten T盲tigkeit als Direktor. Diese Zuwendungen wurden automatisch gem盲脽 der Verg眉tungspolitik f眉r externe Direktoren des Unternehmens gew盲hrt und stellen die 眉blichen Vorstandsverg眉tungsregelungen dar.

SEC Form 4
FORM 4 UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940
OMB APPROVAL
OMB Number: 3235-0287
Estimated average burden
hours per response: 0.5
Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).
Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.
1. Name and Address of Reporting Person*
Dar Zavain
(Last) (First) (Middle)
C/O RECURSION PHARMACEUTICALS
41 S. RIO GRANDE STREET
(Street)
SALT LAKE CITY UT 84101
(City) (State) (Zip)
2. Issuer Name and Ticker or Trading Symbol
RECURSION PHARMACEUTICALS, INC. [ RXRX ] 		5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)
X Director 10% Owner
Officer (give title below) Other (specify below)
3. Date of Earliest Transaction (Month/Day/Year)
06/18/2025
4. If Amendment, Date of Original Filed (Month/Day/Year)
 6. Individual or Joint/Group Filing (Check Applicable Line)
X Form filed by One Reporting Person
Form filed by More than One Reporting Person
Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3) 2. Transaction Date (Month/Day/Year) 2A. Deemed Execution Date, if any (Month/Day/Year) 3. Transaction Code (Instr. 8) 4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5) 5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4) 6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 7. Nature of Indirect Beneficial Ownership (Instr. 4)
Code V Amount (A) or (D) Price
Class A Common Stock 06/18/2025 A(1) 22,016 A $0 132,893 D
Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned
(e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3) 2. Conversion or Exercise Price of Derivative Security 3. Transaction Date (Month/Day/Year) 3A. Deemed Execution Date, if any (Month/Day/Year) 4. Transaction Code (Instr. 8) 5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5) 6. Date Exercisable and Expiration Date (Month/Day/Year) 7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4) 8. Price of Derivative Security (Instr. 5) 9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4) 10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 11. Nature of Indirect Beneficial Ownership (Instr. 4)
Code V (A) (D) Date Exercisable Expiration Date Title Amount or Number of Shares
Stock Option (Right to Buy) $5.11 06/18/2025 A 44,031 (2) 06/18/2035 Class A Common Stock 44,031 $0 44,031 D
Explanation of Responses:
1. Represents a grant of restricted stock units automatically granted pursuant to the Issuer's Outside Director Compensation Policy. The restricted stock units will vest on the earlier of June 18, 2026 or the day prior to the Issuer's 2026 Annual Meeting of Stockholders, subject to the Reporting Person's continued service to the Issuer.
2. The shares subject to this option will vest and become exercisable on the earlier of June 18, 2026 or the date of the Issuer's 2026 Annual Meeting of Stockholders, subject to the Reporting Person's continued service to the Issuer.
Remarks:
/s/ Jonathan Golightly, attorney-in-fact 06/23/2025
** Signature of Reporting Person Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

Source:

FAQ

What insider trading activity occurred at RXRX on June 18, 2025?

Director Zavain Dar received two equity grants: 22,016 restricted stock units (RSUs) and stock options to purchase 44,031 shares of Class A Common Stock at an exercise price of $5.11 per share.

When do Zavain Dar's RXRX stock options and RSUs vest?

Both the RSUs and stock options will vest on the earlier of June 18, 2026 or the day prior to Recursion Pharmaceuticals' 2026 Annual Meeting of Stockholders, subject to Dar's continued service to the company.

How many shares of RXRX does Zavain Dar own after the June 2025 grants?

Following the transactions, Dar directly owns 132,893 shares of Class A Common Stock and 44,031 stock options. All holdings are held in direct ownership form.

What is the exercise price and expiration date of RXRX stock options granted to Dar?

The stock options were granted with an exercise price of $5.11 per share and expire on June 18, 2035, ten years from the grant date.

Was this RXRX insider transaction part of a 10b5-1 trading plan?

No, this transaction was not made pursuant to a 10b5-1 trading plan. The grants were automatic awards made under Recursion Pharmaceuticals' Outside Director Compensation Policy.
Stock RXRX logo
Recursion Pharmaceuticals, Inc.

NASDAQ:RXRX

RXRX Rankings

#2634 Ranked by Market Cap
N/A Ranked by Dividends

RXRX Latest News

Aug 5, 2025
Recursion Reports Second Quarter 2025 Financial Results and Provides Business Update
Jul 29, 2025
Recursion to Report Second Quarter 2025 Business Updates and Financial Results on August 5th
Jul 8, 2025
Recursion Acquires Full Rights to REV102, a Potential First-in-Class Oral ENPP1 Inhibitor for Hypophosphatasia
Jun 6, 2025
MIT and Recursion Release Boltz-2: Next Generation AI Model to Predict Binding Affinity at Unprecedented Speed, Scale, and Accuracy
May 30, 2025
Recursion to Participate in Upcoming Investor Conferences

RXRX Latest SEC Filings

Aug 5, 2025
[10-Q] Recursion Pharmaceuticals, Inc. Quarterly Earnings Report
Aug 5, 2025
[8-K] Recursion Pharmaceuticals, Inc. Reports Material Event
Jul 8, 2025
[8-K] Recursion Pharmaceuticals, Inc. Reports Material Event
Jul 8, 2025
[424B7] Recursion Pharmaceuticals, Inc. Prospectus Filed Pursuant to Rule 424(b)(7)
Jul 3, 2025
[Form 4] Recursion Pharmaceuticals, Inc. Insider Trading Activity

RXRX Stock Data

2.46B
406.37M
4.78%
69.05%
26.65%
Biotechnology
Biological Products, (no Disgnostic Substances)
United States
SALT LAKE CITY